Kymanox
58 Case Studies
A Kymanox Case Study
The pharmaceutical organization transitioning from a drug-only portfolio faced a significant challenge when post-market complaint data for a Class II combination product necessitated corrective action across the US, EU, and Canadian markets simultaneously. The organization lacked prior human factors work or internal expertise and needed to optimize patient labeling for over 50 diverse user groups. They engaged Kymanox for its human factors and regulatory affairs services to address these multi-market regulatory requirements.
Kymanox implemented a strategic solution by iterating the device design and instructional materials based on formative data from the EU. They then executed a US validation study leveraging those insights and further iterated the design. Kymanox strategically submitted the combined EU and US validation data to Health Canada, maximizing regulatory efficiency. This approach resulted in FDA New Drug Application approval for the combination product. Kymanox also leveraged the validation data for a second product's submission, eliminating the need for additional HF testing and accelerating its FDA approval, while establishing a reusable framework for the client's future combination products.
Pharmaceutical Organization Transitioning From a Drug-only Portfolio